Literature DB >> 303166

Metabolism of procainamide and p-aminobenzoic acid in patients with chronic liver disease.

P du Souich, S Erill.   

Abstract

Procainamide acetylation and hydrolysis, procainamide-derived p-amino-benzoic acid acetylation, and plasma hydrolysis of procaine were studied in normal volunteers and in 20 patients with chronic liver disease, Impairment of procainamide acetylation was evident in the patients, but no correlations were demonstrable between the degree of impairment and the severity of the disease. On the other hand, procainamide hydroylsis was diminished in liver disease, and as indicated by depression of serum albumin levels and plasma prothrombin activity this alteration did correlate with the degree of impairment of liver function. Procaine hydrolysis in plasma was also affected, the mean in vitro plasma half-life being prolonged in the patients with liver disease and correlating with the degree of hepatic impairment. A correlation of procainamide hydrolysis with procaine hydrolysis was also observed. Finally, acetylation of procainamide-derived p-aminobenzoic acid appeared to increase in patients with liver disease, the degree of acetylation increasing with decreasing procainamide hydrolysis capacity.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 303166     DOI: 10.1002/cpt1977225part1588

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  10 in total

Review 1.  Clinical pharmacokinetics in patients with liver disease.

Authors:  A J McLean; D J Morgan
Journal:  Clin Pharmacokinet       Date:  1991-07       Impact factor: 6.447

Review 2.  Effects of cardiovascular disease on pharmacokinetics.

Authors:  V Rodighiero
Journal:  Cardiovasc Drugs Ther       Date:  1989-10       Impact factor: 3.727

3.  Metabolomics reveals the metabolic map of procainamide in humans and mice.

Authors:  Fei Li; Andrew D Patterson; Kristopher W Krausz; Bernhard Dick; Felix J Frey; Frank J Gonzalez; Jeffrey R Idle
Journal:  Biochem Pharmacol       Date:  2012-02-24       Impact factor: 5.858

4.  Effect of ranitidine on procainamide disposition.

Authors:  B K Martin
Journal:  Br J Clin Pharmacol       Date:  1985-06       Impact factor: 4.335

Review 5.  Drug acetylation in liver disease.

Authors:  M Levy; Y Caraco; G Geisslinger
Journal:  Clin Pharmacokinet       Date:  1998-03       Impact factor: 6.447

Review 6.  Practical optimisation of antiarrhythmic drug therapy using pharmacokinetic principles.

Authors:  J L Bauman; M D Schoen; T J Hoon
Journal:  Clin Pharmacokinet       Date:  1991-02       Impact factor: 6.447

7.  Metabolism of procainamide in patients with chronic heart failure, chronic respiratory failure and chronic renal failure.

Authors:  P du Souich; S Erill
Journal:  Eur J Clin Pharmacol       Date:  1978-11-09       Impact factor: 2.953

Review 8.  Antiarrhythmics: elimination and dosage considerations in hepatic impairment.

Authors:  Ulrich Klotz
Journal:  Clin Pharmacokinet       Date:  2007       Impact factor: 6.447

9.  The effects of 2-chloroprocaine on coagulation and fibrinolysis in the parturient: an in vitro study.

Authors:  Bhavani Shankar Kodali; Monica Sa Rego; A Murat Kaynar; Richard D Urman
Journal:  J Anesth       Date:  2014-04-19       Impact factor: 2.078

10.  Procaine hydrolysis defect in uraemia does not appear to be due to carbamylation of plasma esterases.

Authors:  R Calvo; R Carlos; S Erill
Journal:  Eur J Clin Pharmacol       Date:  1983       Impact factor: 2.953

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.